Nifuroxazide

Summary

Nifuroxazide (CHEMBL244888) is a phase-3 clinical-stage small molecule (ATC A07AX03); indicated across 2 conditions including brain disorder and inflammatory bowel disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A07AX03
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 275.22 Da · C12H9N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL244888
Name	Nifuroxazide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5337997
ATC	A07AX03
Molecular formula	C12H9N3O5
Molecular weight	275.22
InChIKey	YCWSUKQGVSGXJO-NTUHNPAUSA-N

SMILES: C1=CC(=CC=C1C(=O)N/N=C/C2=CC=C(O2)[N+](=O)[O-])O

IUPAC name: 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide

Also known as: Ercefuryl 200, Nifuroxazida, Nifuroxazide, NSC-759261, RC-27109, SJ000287313, SID11532872, NIFUROXAZIDE

Patent coverage: 483 distinct patent families (1,459 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Fructose-bisphosphate aldolase, Prelamin-A/C, Ras-related protein Rab-9A, Microphthalmia-associated transcription factor, Menin/Histone-lysine N-methyltransferase MLL, DNA polymerase beta, Lysosomal alpha-glucosidase.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KDM4E	5.55	Potency	2818	nM	CHEMBL_ACT_3742214
STAT3	5.52	EC50	3000	nM	CHEMBL_ACT_12101624
NPSR1	5.45	Potency	3548	nM	CHEMBL_ACT_3607514
NPSR1	5.45	Potency	3548	nM	CHEMBL_ACT_5049272
RAB9A	5.4	Potency	3981	nM	CHEMBL_ACT_3850060
MITF	5.28	AC50	5202	nM	CHEMBL_ACT_5330785
MITF	5.28	AC50	5202	nM	CHEMBL_ACT_5694544
MITF	5.28	AC50	5202	nM	CHEMBL_ACT_5976060
MAPT	5	Potency	10000	nM	CHEMBL_ACT_4066050

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
brain disorder	3	MONDO:0005560	HP:0001298
inflammatory bowel disease	2	MONDO:0005265	EFO:0003767

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05754996	PHASE3	COMPLETED	Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis
NCT05988528	PHASE2/PHASE3	COMPLETED	Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).